Fermenta Biotech Limited has announced that its Board of Directors, in a meeting held on December 10, 2025, approved a comprehensive fundraising proposal of up to ₹150.00 crore. The plan includes a wide range of financial instruments and issuance modes, providing the company with significant flexibility to strengthen its capital base and support future growth initiatives.
Fundraising Structure and Approved Securities
The board has approved multiple classes of securities, allowing the company to select the most suitable instruments based on market conditions and investor appetite. The proposed fundraising may involve one or more of the following:
| Security Type | Details |
| Equity Shares | Direct equity issuance |
| Convertible Securities | Instruments convertible into equity |
| Warrants | Rights to purchase shares at a predetermined price |
| Fully Convertible Debentures (FCDs) | Debt securities fully convertible to equity |
| Partly Convertible Debentures (PCDs) | Instruments with both debt and equity characteristics |
| Non-Convertible Debentures (NCDs) with Warrants | Pure debt offering bundled with equity-linked rights |
| Convertible Preference Shares | Preferred securities with conversion features |
Issuance Methods and Execution Flexibility
Fermenta Biotech has retained the option to raise funds using multiple issuance routes. This flexible framework enables the company to optimize pricing, timing, and investor participation.
| Issuance Mode | Description |
| Public Issue | Offering open to retail and institutional investors |
| Rights Issue | Issuance to existing shareholders in proportion to their holdings |
| Preferential Allotment | Targeted issuance to selected investors |
| Private Placement | Non-public offering to qualified investors |
| Qualified Institutions Placement (QIP) | Fast-track equity raise from institutional investors |
| Multiple Tranches | Fundraising in staged phases depending on requirements |
Regulatory Compliance and Disclosure
The company has filed the required disclosures under Regulation 30 of SEBI (LODR) Regulations, providing clarity on the fundraising structure, modes, and regulatory conditions. The issuance may be executed in one or more tranches depending on market conditions and internal capital needs.
| Regulatory Parameter | Details |
| Maximum Amount | ₹150 crore |
| SEBI Regulation | Listing Obligations and Disclosure Requirements |
| Scrip Code | 506414 |
| Pricing Mechanism | As per applicable regulatory guidelines |
| Shareholder Approval | To be obtained separately at the appropriate stage |
This development also aligns with an earlier intimation issued on December 7, 2025, reflecting an ongoing strategic review by the Board. The proposed fundraising is subject to necessary regulatory and statutory approvals, as well as separate shareholder approval at the appropriate time.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.